Claims for Patent: 6,846,299

Summary for Patent: 6,846,299

Title:	Method for continuous recirculating peritoneal dialysis
Abstract:	Method for a continuous recirculating peritoneal dialysis wherein the peritoneal dialysis fluid is infused into a peritoneal cavity of a patient and then, typically on a continuous process basis a portion of the dialysis fluid is sequentially drained from the cavity, cleansed through an extracorpreal dialyzer, and reinfused into the cavity. The dialysis fluid contains as an osmotic agent a substance which does not substantially permeate through pores of hollow fiber membrane of an extracorporeal dialyzer, preferably an osmotic agent having a molecular weight of about 20,000 to about 100,000. The supplemented amount of the osmotic agent is reduced or not needed during the dialysis.
Inventor(s):	Masuda; Toshiaki (Osaka, JP), Yamamoto; Hidetoshi (Osaka, JP)
Assignee:	Nipro Corporation (Osaka, JP)
Application Number:	10/171,655
Patent Claims:	1. A method for a continuous recirculating peritoneal dialysis comprising i) infusing a peritoneal dialysis fluid in a peritoneal cavity, said fluid comprising albumin in an amount of about 20 to about 250 g/L, sodium ions in an amount of about 130 to about 140 mEq/L, magnesium ions in an amount of about 0.5 to about 2.0 mEq/L, calcium ions in an amount of about 3.0 to about 4.5 mEq/L, chloride ions in an amount of about 95 to about 110 mEq/L, and lactate ions in an amount of about 35 to about 40 mEq/L ii) sequentially draining the peritoneal dialysis fluid out of the peritoneal cavity, iii) cleansing the peritoneal dialysis fluid through an extracorporeal dialyzer, and iv) reinfusing the cleansed peritoneal fluid into the peritoneal cavity. 2. The method for a continuous recirculating peritoneal dialysis as claimed in claim 1, wherein the concentration of albumin is from about 70 to about 150 g/L. 3. The method for a continuous recirculating peritoneal dialysis as claimed in claim 1, wherein the albumin comprises human serum albumin. 4. A method for dialyzing a patient which comprises (a) plating a fluid pathway in a peritoneum of the patient, (b) infusing a peritoneal dialysis fluid comprising albumin in an amount of about 20 to about 250 g/L, sodium ions in an amount of about 130 to about 140 mEq/L, magnesium ions in an amount of about 0.5 to about 2.0 mEq/L, calcium ions in an amount of about 3.0 to about 4.5 mEq/L, chloride ions in an amount of about 95 to about 110 mEq/L, and lactate ions in an amount of about 35 to about 40 mEq/L into a peritoneal cavity, (c) sequentially draining the peritoneal dialysis fluid out of the peritoneal cavity, (d) transferring said peritoneal dialysis fluid to an extracorporeal dialyzer which consists of hollow fiber membranes, (e) cleansing the transferred peritoneal dialysis fluid in the dialyzer using a detergent solution and (f) reinfusing the cleansed peritoneal dialysis fluid into the peritoneum. 5. The method as claimed in claim 4, wherein the fluid pathway is a catheter. 6. The method as claimed in claim 4, wherein the extracorporeal dialyzer consists of a hollow fiber membrane having a separation limitation of about 2,000 to about 10,000 daltons.

Details for Patent 6,846,299

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2018-06-17
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2018-06-17
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2018-06-17
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2018-06-17
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2018-06-17